AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
Previously, Amgen filed patent infringement lawsuits against biosimilar companies including the Swiss Sandoz, South Korea's Celltrion, South Korea's Samsung Bioepis, and Germany's Fresenius Kabi.
South Korea-based Celltrion today announced that the US Food and Drug Administration (FDA) has approved Stoboclo and Osenvelt ...
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz ...